Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in P
Go back to Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in P| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 81.10 +1.39 (1.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.71 | 52 Week High | $10.00 | |||
| Open | $80.03 | 52 Week Low | $3.22 | |||
| Day High | $82.31 | P/E | N/A | |||
| Day Low | $79.22 | EPS | $-0.46 | |||
| Volume | 299,707 | |||||
